Volta Medical has announced the U.S. launch of its AF-Xplorer II system, the company’s ‘next-generation’ AI solution which it says is designed to simplify real-time assessment of complex AF.
The company says the new system builds on the success of its predecessor, and introduces several new advancements, including: high stability analysis, which provides physicians with an objective method for identifying regions of interest; expanded catheter compatibility, including the ability to analyse signals with the Medtronic sphere-9 mapping and ablation catheter; and integration with the GE HealthCare CardioLab AltiX AI.i recording system.
Volta says the new advancements will allow electrophysiologists to deliver more efficient procedures.
Earlier in 2025, the AF-Xplorer II received CE Mark approval in Europe, and has been adopted in clinical practice, providing experience that will now be extended to U.S. physicians.
“From the beginning, our mission has been to make a real difference in the lives of patients with complex AF, knowing that despite decades of technical and procedural innovation, efficacy has remained virtually unchanged,” said Théophile Mohr Durdez, CEO and Co-Founder of Volta Medical. “AF-Xplorer II represents a leap forward in both the specificity and interoperability of our algorithm. We can provide more information to physicians to be able to streamline procedures and enhance efficiency, all while maintaining the strong performance Volta Medical demonstrated in the TAILORED-AF trial.”
Procedures with AF-Xplorer II were performed by Devi Nair, MD, Director of Cardiac Electrophysiology at St. Bernard’s Heart & Vascular Center. “This next-generation technology represents a meaningful step forward in how we approach complex atrial fibrillation, enabling electrophysiologists to perform procedures with greater consistency. It holds particular promise for the complex atrial fibrillation population, where improving outcomes has historically been a significant challenge.”
